vs
Side-by-side financial comparison of IDEX Corporation (IEX) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $398.4M, roughly 1.6× IDEX Corporation). Royalty Pharma plc runs the higher net margin — 34.4% vs 30.1%, a 4.3% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -29.4%).
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
IEX vs RPRX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $398.4M | $622.0M |
| Net Profit | $120.0M | $214.2M |
| Gross Margin | 99.9% | — |
| Operating Margin | 43.3% | 62.4% |
| Net Margin | 30.1% | 34.4% |
| Revenue YoY | 16.7% | 4.8% |
| Net Profit YoY | 25.7% | 2.9% |
| EPS (diluted) | $1.61 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | — | ||
| Q4 25 | $899.1M | $622.0M | ||
| Q3 25 | $878.7M | $609.3M | ||
| Q2 25 | $865.4M | $578.7M | ||
| Q1 25 | $814.3M | $568.2M | ||
| Q4 24 | $862.9M | $593.6M | ||
| Q3 24 | $798.2M | $564.7M |
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | — | ||
| Q4 25 | $128.3M | $214.2M | ||
| Q3 25 | $127.8M | $288.2M | ||
| Q2 25 | $131.6M | $30.2M | ||
| Q1 25 | $95.5M | $238.3M | ||
| Q4 24 | $123.2M | $208.2M | ||
| Q3 24 | $119.1M | $544.0M |
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | — | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 45.3% | — | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 44.3% | — |
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | 62.4% | ||
| Q3 25 | 21.1% | 70.1% | ||
| Q2 25 | 21.7% | 36.3% | ||
| Q1 25 | 17.4% | 94.0% | ||
| Q4 24 | 19.2% | 60.9% | ||
| Q3 24 | 21.0% | — |
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | — | ||
| Q4 25 | 14.3% | 34.4% | ||
| Q3 25 | 14.5% | 47.3% | ||
| Q2 25 | 15.2% | 5.2% | ||
| Q1 25 | 11.7% | 41.9% | ||
| Q4 24 | 14.3% | 35.1% | ||
| Q3 24 | 14.9% | 96.3% |
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | — | ||
| Q4 25 | $1.71 | $0.49 | ||
| Q3 25 | $1.70 | $0.67 | ||
| Q2 25 | $1.74 | $0.07 | ||
| Q1 25 | $1.26 | $0.55 | ||
| Q4 24 | $1.61 | $0.46 | ||
| Q3 24 | $1.57 | $1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $586.2M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $4.0B | $9.7B |
| Total Assets | $6.9B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | — | ||
| Q4 25 | $580.0M | $618.7M | ||
| Q3 25 | $593.8M | $938.9M | ||
| Q2 25 | $568.2M | $631.9M | ||
| Q1 25 | $594.1M | $1.1B | ||
| Q4 24 | $620.8M | $929.0M | ||
| Q3 24 | $633.2M | $950.1M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $9.0B | ||
| Q3 25 | $1.9B | $8.9B | ||
| Q2 25 | $1.9B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.6B | ||
| Q3 24 | $2.1B | $7.6B |
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $9.7B | ||
| Q3 25 | $4.0B | $9.6B | ||
| Q2 25 | $4.0B | $9.5B | ||
| Q1 25 | $3.9B | $9.8B | ||
| Q4 24 | $3.8B | $10.3B | ||
| Q3 24 | $3.8B | $10.3B |
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $19.6B | ||
| Q3 25 | $7.0B | $19.3B | ||
| Q2 25 | $6.9B | $18.3B | ||
| Q1 25 | $6.8B | $17.6B | ||
| Q4 24 | $6.7B | $18.2B | ||
| Q3 24 | $7.0B | $18.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | 0.92× | ||
| Q3 25 | 0.48× | 0.93× | ||
| Q2 25 | 0.46× | 0.84× | ||
| Q1 25 | 0.50× | 0.78× | ||
| Q4 24 | 0.52× | 0.74× | ||
| Q3 24 | 0.55× | 0.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | $86.0M | — |
| FCF MarginFCF / Revenue | 21.6% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $654.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | $827.1M | ||
| Q3 25 | $203.5M | $702.6M | ||
| Q2 25 | $161.7M | $364.0M | ||
| Q1 25 | $105.7M | $596.1M | ||
| Q4 24 | $172.6M | $742.5M | ||
| Q3 24 | $205.3M | $703.6M |
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | — | ||
| Q3 25 | $188.7M | — | ||
| Q2 25 | $146.9M | — | ||
| Q1 25 | $91.4M | — | ||
| Q4 24 | $157.1M | — | ||
| Q3 24 | $191.6M | — |
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 18.2% | — | ||
| Q3 24 | 24.0% | — |
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 1.7% | — |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | 3.86× | ||
| Q3 25 | 1.59× | 2.44× | ||
| Q2 25 | 1.23× | 12.06× | ||
| Q1 25 | 1.11× | 2.50× | ||
| Q4 24 | 1.40× | 3.57× | ||
| Q3 24 | 1.72× | 1.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IEX
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
